Physician profile
Brian A Hanlon
NPI 1205867579
$3,798.88
in general payments reported to CMS, 2019-2025
26 companies · $431 in 2025
The $431 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $212 · 2021: $562 · 2022: $705 · 2023: $634 · 2024: $882 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $716.73 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $402.13 | 2020-2024 | Lifevest |
| Kestra Medical Technology Services, INC. | $322.48 | 2023-2024 | Assure Wcd |
| Cvrx, INC. | $306.29 | 2022-2025 | Barostim Neo System |
| Pfizer INC. | $270.11 | 2020-2025 | |
| Medtronic, INC. | $265.38 | 2022 | |
| Amgen INC. | $248.87 | 2019-2025 | Repatha, Repatha |
| W. L. Gore & Associates, INC. | $156.28 | 2024-2025 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.34 | 2021-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $122.01 | 2024 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $107.80 | 2019-2024 | |
| Astellas Pharma US INC | $105.36 | 2021 | |
| Sanofi-Aventis U.S. LLC | $93.75 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $88.54 | 2024-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $85.70 | 2024 | Watchman Flx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $80.67 | 2025 | Indigo System |
| Bayer Healthcare Pharmaceuticals INC. | $70.95 | 2024-2025 | |
| Philips North America LLC | $67.78 | 2023 | |
| Terumo Medical Corporation | $26.49 | 2020 | |
| Heartflow, INC. | $25.10 | 2025 | |
| Irhythm Technologies, INC. | $23.13 | 2019 | |
| Astellas Pharma Global Development | $20.71 | 2025 | Xtandi |
| Scpharmaceuticals INC. | $19.91 | 2025 | |
| Abbott Laboratories | $18.49 | 2020 | |
| Merck Sharp & Dohme LLC | $14.87 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hanlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.